#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Tom
1-1	0-3	Tom	person	new	coref	3-1[4_0]

#Text=Jefferson ( epidemiologist )
2-1	4-13	Jefferson	place[2]	new[2]	_	_
2-2	14-15	(	place[2]	new[2]	_	_
2-3	16-30	epidemiologist	place[2]|person	new[2]|new	coref	4-2[5_0]
2-4	31-32	)	place[2]	new[2]	_	_

#Text=Tom Jefferson
3-1	33-36	Tom	person[4]	giv[4]	coref	5-1[0_4]
3-2	37-46	Jefferson	person[4]	giv[4]	_	_

#Text=is a British epidemiologist , based in Rome , Italy , [ 1 ] who works for the Cochrane Collaboration .
4-1	47-49	is	_	_	_	_
4-2	50-51	a	person[5]	giv[5]	_	_
4-3	52-59	British	person[5]	giv[5]	_	_
4-4	60-74	epidemiologist	person[5]	giv[5]	_	_
4-5	75-76	,	_	_	_	_
4-6	77-82	based	_	_	_	_
4-7	83-85	in	_	_	_	_
4-8	86-90	Rome	place[6]	new[6]	_	_
4-9	91-92	,	place[6]	new[6]	_	_
4-10	93-98	Italy	place[6]	new[6]	_	_
4-11	99-100	,	_	_	_	_
4-12	101-102	[	_	_	_	_
4-13	103-104	1	abstract	new	coref	19-37
4-14	105-106	]	_	_	_	_
4-15	107-110	who	_	_	_	_
4-16	111-116	works	_	_	_	_
4-17	117-120	for	_	_	_	_
4-18	121-124	the	organization[9]	new[9]	coref	5-9[13_9]
4-19	125-133	Cochrane	person|organization[9]	new|new[9]	coref	5-22[16_0]
4-20	134-147	Collaboration	organization[9]	new[9]	_	_
4-21	148-149	.	_	_	_	_

#Text=Jefferson is an author and editor of the Cochrane Collaboration 's acute respiratory infections group , as well as part of four other Cochrane groups . [ 2 ]
5-1	150-159	Jefferson	person	giv	coref	5-3[11_0]
5-2	160-162	is	_	_	_	_
5-3	163-165	an	person[11]	giv[11]	ana	6-1[0_11]
5-4	166-172	author	person[11]	giv[11]	_	_
5-5	173-176	and	person[11]	giv[11]	_	_
5-6	177-183	editor	person[11]|person[12]	giv[11]|new[12]	_	_
5-7	184-186	of	person[11]|person[12]	giv[11]|new[12]	_	_
5-8	187-190	the	person[11]|person[12]|organization[15]	giv[11]|new[12]|new[15]	_	_
5-9	191-199	Cochrane	person[11]|person[12]|organization[13]|organization[15]	giv[11]|new[12]|giv[13]|new[15]	_	_
5-10	200-213	Collaboration	person[11]|person[12]|organization[13]|organization[15]	giv[11]|new[12]|giv[13]|new[15]	_	_
5-11	214-216	's	person[11]|person[12]|organization[13]|organization[15]	giv[11]|new[12]|giv[13]|new[15]	_	_
5-12	217-222	acute	person[11]|person[12]|organization[15]	giv[11]|new[12]|new[15]	_	_
5-13	223-234	respiratory	person[11]|person[12]|abstract[14]|organization[15]	giv[11]|new[12]|new[14]|new[15]	_	_
5-14	235-245	infections	person[11]|person[12]|abstract[14]|organization[15]	giv[11]|new[12]|new[14]|new[15]	_	_
5-15	246-251	group	person[11]|person[12]|organization[15]	giv[11]|new[12]|new[15]	_	_
5-16	252-253	,	person[11]	giv[11]	_	_
5-17	254-256	as	person[11]	giv[11]	_	_
5-18	257-261	well	person[11]	giv[11]	_	_
5-19	262-264	as	person[11]	giv[11]	_	_
5-20	265-269	part	person[11]	giv[11]	_	_
5-21	270-272	of	person[11]	giv[11]	_	_
5-22	273-277	four	person[11]|person[16]	giv[11]|giv[16]	coref	9-5[0_16]
5-23	278-283	other	person[11]|person[16]	giv[11]|giv[16]	_	_
5-24	284-292	Cochrane	person[11]|person[16]	giv[11]|giv[16]	_	_
5-25	293-299	groups	person[11]|person[16]	giv[11]|giv[16]	_	_
5-26	300-301	.	_	_	_	_
5-27	302-303	[	_	_	_	_
5-28	304-305	2	abstract	new	coref	6-17
5-29	306-307	]	_	_	_	_

#Text=He is also an advisor to the Italian National Agency for Regional Health Services . [ 2 ]
6-1	308-310	He	person	giv	coref	6-4[19_0]
6-2	311-313	is	_	_	_	_
6-3	314-318	also	_	_	_	_
6-4	319-321	an	person[19]	giv[19]	coref	8-1[0_19]
6-5	322-329	advisor	person[19]	giv[19]	_	_
6-6	330-332	to	person[19]	giv[19]	_	_
6-7	333-336	the	person[19]|organization[20]	giv[19]|new[20]	coref	16-13[78_20]
6-8	337-344	Italian	person[19]|organization[20]	giv[19]|new[20]	_	_
6-9	345-353	National	person[19]|organization[20]	giv[19]|new[20]	_	_
6-10	354-360	Agency	person[19]|organization[20]	giv[19]|new[20]	_	_
6-11	361-364	for	person[19]|organization[20]	giv[19]|new[20]	_	_
6-12	365-373	Regional	person[19]|organization[20]|abstract[21]	giv[19]|new[20]|new[21]	_	_
6-13	374-380	Health	person[19]|organization[20]|abstract[21]	giv[19]|new[20]|new[21]	_	_
6-14	381-389	Services	person[19]|organization[20]|abstract[21]	giv[19]|new[20]|new[21]	_	_
6-15	390-391	.	_	_	_	_
6-16	392-393	[	_	_	_	_
6-17	394-395	2	abstract	giv	_	_
6-18	396-397	]	_	_	_	_

#Text=In 1999
7-1	398-400	In	_	_	_	_
7-2	401-405	1999	time	new	_	_

#Text=Jefferson was one of the founding members of the Brighton Collaboration along with Harald Heijbel , Ulrich Heininger , and Elisabeth Loupi . [ 3 ]
8-1	406-415	Jefferson	person	giv	ana	9-1
8-2	416-419	was	_	_	_	_
8-3	420-423	one	person[25]	new[25]	_	_
8-4	424-426	of	person[25]	new[25]	_	_
8-5	427-430	the	person[25]|person[26]	new[25]|new[26]	_	_
8-6	431-439	founding	person[25]|person[26]	new[25]|new[26]	_	_
8-7	440-447	members	person[25]|person[26]	new[25]|new[26]	_	_
8-8	448-450	of	person[25]|person[26]	new[25]|new[26]	_	_
8-9	451-454	the	person[25]|person[26]|abstract[28]	new[25]|new[26]|new[28]	_	_
8-10	455-463	Brighton	person[25]|person[26]|person|abstract[28]	new[25]|new[26]|new|new[28]	_	_
8-11	464-477	Collaboration	person[25]|person[26]|abstract[28]	new[25]|new[26]|new[28]	_	_
8-12	478-483	along	person[25]|person[26]	new[25]|new[26]	_	_
8-13	484-488	with	person[25]|person[26]	new[25]|new[26]	_	_
8-14	489-495	Harald	person[25]|person[26]|person[29]	new[25]|new[26]|new[29]	_	_
8-15	496-503	Heijbel	person[25]|person[26]|person[29]	new[25]|new[26]|new[29]	_	_
8-16	504-505	,	person[25]|person[26]	new[25]|new[26]	_	_
8-17	506-512	Ulrich	person[25]|person[26]|person[30]	new[25]|new[26]|new[30]	_	_
8-18	513-522	Heininger	person[25]|person[26]|person[30]	new[25]|new[26]|new[30]	_	_
8-19	523-524	,	person[25]|person[26]	new[25]|new[26]	_	_
8-20	525-528	and	person[25]|person[26]	new[25]|new[26]	_	_
8-21	529-538	Elisabeth	person[25]|person[26]|person[31]	new[25]|new[26]|new[31]	_	_
8-22	539-544	Loupi	person[25]|person[26]|person[31]	new[25]|new[26]|new[31]	_	_
8-23	545-546	.	_	_	_	_
8-24	547-548	[	_	_	_	_
8-25	549-550	3	abstract	new	_	_
8-26	551-552	]	_	_	_	_

#Text=He has worked on Cochrane reviews examining the effectiveness of the anti-viral oseltamivir and the influenza vaccine . [ 4 ]
9-1	553-555	He	person	giv	coref	12-1
9-2	556-559	has	_	_	_	_
9-3	560-566	worked	_	_	_	_
9-4	567-569	on	_	_	_	_
9-5	570-578	Cochrane	person|abstract[35]	giv|new[35]	coref|coref|coref|coref	17-11|20-1[0_35]|17-11|20-1[0_35]
9-6	579-586	reviews	abstract[35]	new[35]	_	_
9-7	587-596	examining	_	_	_	_
9-8	597-600	the	abstract[36]	new[36]	_	_
9-9	601-614	effectiveness	abstract[36]	new[36]	_	_
9-10	615-617	of	abstract[36]	new[36]	_	_
9-11	618-621	the	abstract[36]|substance[37]	new[36]|new[37]	coref	12-17[0_37]
9-12	622-632	anti-viral	abstract[36]|substance[37]	new[36]|new[37]	_	_
9-13	633-644	oseltamivir	abstract[36]|substance[37]	new[36]|new[37]	_	_
9-14	645-648	and	abstract[36]	new[36]	_	_
9-15	649-652	the	abstract[36]|substance[39]	new[36]|new[39]	coref	19-30[0_39]
9-16	653-662	influenza	abstract[36]|abstract|substance[39]	new[36]|new|new[39]	coref	17-29
9-17	663-670	vaccine	abstract[36]|substance[39]	new[36]|new[39]	_	_
9-18	671-672	.	_	_	_	_
9-19	673-674	[	_	_	_	_
9-20	675-676	4	abstract	new	coref	12-20
9-21	677-678	]	_	_	_	_

#Text=Notable work
10-1	679-686	Notable	abstract[41]	new[41]	_	_
10-2	687-691	work	abstract[41]	new[41]	_	_

#Text=In 2009
11-1	692-694	In	_	_	_	_
11-2	695-699	2009	time	new	coref	15-22

#Text=Jefferson was hired by the governments of Britain and Australia to update a systematic review of oseltamivir . [ 4 ]
12-1	700-709	Jefferson	person	giv	ana	13-2
12-2	710-713	was	_	_	_	_
12-3	714-719	hired	_	_	_	_
12-4	720-722	by	_	_	_	_
12-5	723-726	the	organization[44]	new[44]	_	_
12-6	727-738	governments	organization[44]	new[44]	_	_
12-7	739-741	of	organization[44]	new[44]	_	_
12-8	742-749	Britain	organization[44]|place	new[44]|new	_	_
12-9	750-753	and	organization[44]	new[44]	_	_
12-10	754-763	Australia	organization[44]|place	new[44]|new	_	_
12-11	764-766	to	_	_	_	_
12-12	767-773	update	_	_	_	_
12-13	774-775	a	abstract[47]	new[47]	_	_
12-14	776-786	systematic	abstract[47]	new[47]	_	_
12-15	787-793	review	abstract[47]	new[47]	_	_
12-16	794-796	of	abstract[47]	new[47]	_	_
12-17	797-808	oseltamivir	abstract[47]|substance	new[47]|giv	coref	17-19
12-18	809-810	.	_	_	_	_
12-19	811-812	[	_	_	_	_
12-20	813-814	4	abstract	giv	coref	13-17
12-21	815-816	]	_	_	_	_

#Text=Initially he had a great deal of trouble getting results of the original trials . [ 4 ]
13-1	817-826	Initially	_	_	_	_
13-2	827-829	he	person	giv	coref	17-4
13-3	830-833	had	_	_	_	_
13-4	834-835	a	abstract[51]	new[51]	_	_
13-5	836-841	great	abstract[51]	new[51]	_	_
13-6	842-846	deal	abstract[51]	new[51]	_	_
13-7	847-849	of	abstract[51]	new[51]	_	_
13-8	850-857	trouble	abstract[51]|abstract	new[51]|new	_	_
13-9	858-865	getting	_	_	_	_
13-10	866-873	results	abstract[53]	new[53]	_	_
13-11	874-876	of	abstract[53]	new[53]	_	_
13-12	877-880	the	abstract[53]|abstract[54]	new[53]|new[54]	coref	14-5[0_54]
13-13	881-889	original	abstract[53]|abstract[54]	new[53]|new[54]	_	_
13-14	890-896	trials	abstract[53]|abstract[54]	new[53]|new[54]	_	_
13-15	897-898	.	_	_	_	_
13-16	899-900	[	_	_	_	_
13-17	901-902	4	abstract	giv	coref	14-25
13-18	903-904	]	_	_	_	_

#Text=Previous researchers had published trials without seeing the underlying data and it appeared that some of the published papers used ghost writers . [ 4 ]
14-1	905-913	Previous	person[56]	new[56]	ana	14-15[59_56]
14-2	914-925	researchers	person[56]	new[56]	_	_
14-3	926-929	had	_	_	_	_
14-4	930-939	published	_	_	_	_
14-5	940-946	trials	abstract	giv	coref	15-9[65_0]
14-6	947-954	without	_	_	_	_
14-7	955-961	seeing	_	_	_	_
14-8	962-965	the	abstract[58]	new[58]	coref	15-14[0_58]
14-9	966-976	underlying	abstract[58]	new[58]	_	_
14-10	977-981	data	abstract[58]	new[58]	_	_
14-11	982-985	and	_	_	_	_
14-12	986-988	it	_	_	_	_
14-13	989-997	appeared	_	_	_	_
14-14	998-1002	that	_	_	_	_
14-15	1003-1007	some	person[59]	giv[59]	ana	15-19[0_59]
14-16	1008-1010	of	person[59]	giv[59]	_	_
14-17	1011-1014	the	person[59]|object[60]	giv[59]|new[60]	_	_
14-18	1015-1024	published	person[59]|object[60]	giv[59]|new[60]	_	_
14-19	1025-1031	papers	person[59]|object[60]	giv[59]|new[60]	_	_
14-20	1032-1036	used	_	_	_	_
14-21	1037-1042	ghost	person[61]	new[61]	_	_
14-22	1043-1050	writers	person[61]	new[61]	_	_
14-23	1051-1052	.	_	_	_	_
14-24	1053-1054	[	_	_	_	_
14-25	1055-1056	4	abstract	giv	ana	15-7
14-26	1057-1058	]	_	_	_	_

#Text=As the company , Roche , that did the trials refused to provide data for independent analysis , their conclusions in 2009 were that benefits could not be shown . [ 4 ]
15-1	1059-1061	As	_	_	_	_
15-2	1062-1065	the	_	_	_	_
15-3	1066-1073	company	_	_	_	_
15-4	1074-1075	,	_	_	_	_
15-5	1076-1081	Roche	organization	new	coref	16-18
15-6	1082-1083	,	_	_	_	_
15-7	1084-1088	that	abstract	giv	coref	15-32
15-8	1089-1092	did	_	_	_	_
15-9	1093-1096	the	abstract[65]	giv[65]	coref	22-6[137_65]
15-10	1097-1103	trials	abstract[65]	giv[65]	_	_
15-11	1104-1111	refused	_	_	_	_
15-12	1112-1114	to	_	_	_	_
15-13	1115-1122	provide	_	_	_	_
15-14	1123-1127	data	abstract	giv	coref	16-11[76_0]
15-15	1128-1131	for	_	_	_	_
15-16	1132-1143	independent	abstract[67]	new[67]	_	_
15-17	1144-1152	analysis	abstract[67]	new[67]	_	_
15-18	1153-1154	,	_	_	_	_
15-19	1155-1160	their	person|abstract[69]	giv|new[69]	coref|coref	19-29[113_0]|19-29[113_0]
15-20	1161-1172	conclusions	abstract[69]	new[69]	_	_
15-21	1173-1175	in	abstract[69]	new[69]	_	_
15-22	1176-1180	2009	abstract[69]|time	new[69]|giv	coref	30-23
15-23	1181-1185	were	_	_	_	_
15-24	1186-1190	that	_	_	_	_
15-25	1191-1199	benefits	abstract	new	_	_
15-26	1200-1205	could	_	_	_	_
15-27	1206-1209	not	_	_	_	_
15-28	1210-1212	be	_	_	_	_
15-29	1213-1218	shown	_	_	_	_
15-30	1219-1220	.	_	_	_	_
15-31	1221-1222	[	_	_	_	_
15-32	1223-1224	4	abstract	giv	coref	16-27
15-33	1225-1226	]	_	_	_	_

#Text=In 2011 Jefferson 's team was provided 22,000 pages of data from the European Medicines Agency and Roche eventually provided 3,000 pages of data . [ 4 ]
16-1	1227-1229	In	_	_	_	_
16-2	1230-1234	2011	time	new	_	_
16-3	1235-1244	Jefferson	person[74]	new[74]	_	_
16-4	1245-1247	's	person[74]	new[74]	_	_
16-5	1248-1252	team	person[74]	new[74]	_	_
16-6	1253-1256	was	_	_	_	_
16-7	1257-1265	provided	_	_	_	_
16-8	1266-1272	22,000	object[75]	new[75]	_	_
16-9	1273-1278	pages	object[75]	new[75]	_	_
16-10	1279-1281	of	object[75]	new[75]	_	_
16-11	1282-1286	data	object[75]|abstract[76]	new[75]|giv[76]	coref	16-24[0_76]
16-12	1287-1291	from	object[75]|abstract[76]	new[75]|giv[76]	_	_
16-13	1292-1295	the	object[75]|abstract[76]|organization[78]	new[75]|giv[76]|giv[78]	_	_
16-14	1296-1304	European	object[75]|abstract[76]|organization[77]|organization[78]	new[75]|giv[76]|new[77]|giv[78]	_	_
16-15	1305-1314	Medicines	object[75]|abstract[76]|organization[77]|organization[78]	new[75]|giv[76]|new[77]|giv[78]	_	_
16-16	1315-1321	Agency	object[75]|abstract[76]|organization[78]	new[75]|giv[76]|giv[78]	_	_
16-17	1322-1325	and	_	_	_	_
16-18	1326-1331	Roche	organization	giv	_	_
16-19	1332-1342	eventually	_	_	_	_
16-20	1343-1351	provided	_	_	_	_
16-21	1352-1357	3,000	quantity[80]	new[80]	_	_
16-22	1358-1363	pages	quantity[80]	new[80]	_	_
16-23	1364-1366	of	quantity[80]	new[80]	_	_
16-24	1367-1371	data	quantity[80]|abstract	new[80]|giv	_	_
16-25	1372-1373	.	_	_	_	_
16-26	1374-1375	[	_	_	_	_
16-27	1376-1377	4	abstract	giv	_	_
16-28	1378-1379	]	_	_	_	_

#Text=In 2012 , Jefferson was the lead author of another Cochrane review of this data which concluded that oseltamivir did not reduce the number of hospitalizations caused by influenza .
17-1	1380-1382	In	_	_	_	_
17-2	1383-1387	2012	time	new	_	_
17-3	1388-1389	,	_	_	_	_
17-4	1390-1399	Jefferson	person	giv	coref	17-6[85_0]
17-5	1400-1403	was	_	_	_	_
17-6	1404-1407	the	person[85]	giv[85]	coref	18-1[0_85]
17-7	1408-1412	lead	person[85]	giv[85]	_	_
17-8	1413-1419	author	person[85]	giv[85]	_	_
17-9	1420-1422	of	person[85]	giv[85]	_	_
17-10	1423-1430	another	person[85]|abstract[87]	giv[85]|new[87]	coref	18-4[94_87]
17-11	1431-1439	Cochrane	person[85]|person|abstract[87]	giv[85]|giv|new[87]	_	_
17-12	1440-1446	review	person[85]|abstract[87]	giv[85]|new[87]	_	_
17-13	1447-1449	of	person[85]|abstract[87]	giv[85]|new[87]	_	_
17-14	1450-1454	this	person[85]|abstract[87]|abstract[88]	giv[85]|new[87]|new[88]	_	_
17-15	1455-1459	data	person[85]|abstract[87]|abstract[88]	giv[85]|new[87]|new[88]	_	_
17-16	1460-1465	which	_	_	_	_
17-17	1466-1475	concluded	_	_	_	_
17-18	1476-1480	that	_	_	_	_
17-19	1481-1492	oseltamivir	substance	giv	coref	18-11
17-20	1493-1496	did	_	_	_	_
17-21	1497-1500	not	_	_	_	_
17-22	1501-1507	reduce	_	_	_	_
17-23	1508-1511	the	quantity[90]	new[90]	_	_
17-24	1512-1518	number	quantity[90]	new[90]	_	_
17-25	1519-1521	of	quantity[90]	new[90]	_	_
17-26	1522-1538	hospitalizations	quantity[90]|event	new[90]|new	_	_
17-27	1539-1545	caused	_	_	_	_
17-28	1546-1548	by	_	_	_	_
17-29	1549-1558	influenza	abstract	giv	coref	19-7
17-30	1559-1560	.	_	_	_	_

#Text=Jefferson said that this review also found no evidence that oseltamivir stopped complications from the disease . [ 5 ]
18-1	1561-1570	Jefferson	person	giv	ana	19-1
18-2	1571-1575	said	_	_	_	_
18-3	1576-1580	that	_	_	_	_
18-4	1581-1585	this	abstract[94]	giv[94]	coref	26-4[159_94]
18-5	1586-1592	review	abstract[94]	giv[94]	_	_
18-6	1593-1597	also	_	_	_	_
18-7	1598-1603	found	_	_	_	_
18-8	1604-1606	no	abstract[95]	new[95]	coref	20-10[117_95]
18-9	1607-1615	evidence	abstract[95]	new[95]	_	_
18-10	1616-1620	that	abstract[95]	new[95]	_	_
18-11	1621-1632	oseltamivir	abstract[95]|substance	new[95]|giv	_	_
18-12	1633-1640	stopped	abstract[95]	new[95]	_	_
18-13	1641-1654	complications	abstract[95]|abstract	new[95]|new	_	_
18-14	1655-1659	from	_	_	_	_
18-15	1660-1663	the	abstract[98]	new[98]	_	_
18-16	1664-1671	disease	abstract[98]	new[98]	_	_
18-17	1672-1673	.	_	_	_	_
18-18	1674-1675	[	_	_	_	_
18-19	1676-1677	5	abstract	new	_	_
18-20	1678-1679	]	_	_	_	_

#Text=His views about the effectiveness of influenza vaccines and his outspokenness about them are also controversial ; at a 2007 meeting on pandemic preparedness he was shunned by other vaccine researchers and ate alone . [ 1 ]
19-1	1680-1683	His	person|abstract[101]	giv|new[101]	ana|coref|ana|coref	19-10|23-1[146_101]|19-10|23-1[146_101]
19-2	1684-1689	views	abstract[101]	new[101]	_	_
19-3	1690-1695	about	abstract[101]	new[101]	_	_
19-4	1696-1699	the	abstract[101]|abstract[102]	new[101]|new[102]	_	_
19-5	1700-1713	effectiveness	abstract[101]|abstract[102]	new[101]|new[102]	_	_
19-6	1714-1716	of	abstract[101]|abstract[102]	new[101]|new[102]	_	_
19-7	1717-1726	influenza	abstract[101]|abstract[102]|abstract|substance[104]	new[101]|new[102]|giv|new[104]	ana|coref|ana|coref	19-13[0_104]|20-15|19-13[0_104]|20-15
19-8	1727-1735	vaccines	abstract[101]|abstract[102]|substance[104]	new[101]|new[102]|new[104]	_	_
19-9	1736-1739	and	abstract[101]|abstract[102]	new[101]|new[102]	_	_
19-10	1740-1743	his	abstract[101]|abstract[102]|person|abstract[106]	new[101]|new[102]|giv|new[106]	ana|ana	19-25|19-25
19-11	1744-1757	outspokenness	abstract[101]|abstract[102]|abstract[106]	new[101]|new[102]|new[106]	_	_
19-12	1758-1763	about	abstract[101]|abstract[102]|abstract[106]	new[101]|new[102]|new[106]	_	_
19-13	1764-1768	them	abstract[101]|abstract[102]|abstract[106]|substance	new[101]|new[102]|new[106]|giv	coref	20-15[119_0]
19-14	1769-1772	are	_	_	_	_
19-15	1773-1777	also	_	_	_	_
19-16	1778-1791	controversial	_	_	_	_
19-17	1792-1793	;	_	_	_	_
19-18	1794-1796	at	_	_	_	_
19-19	1797-1798	a	event[108]	new[108]	_	_
19-20	1799-1803	2007	event[108]	new[108]	_	_
19-21	1804-1811	meeting	event[108]	new[108]	_	_
19-22	1812-1814	on	event[108]	new[108]	_	_
19-23	1815-1823	pandemic	event[108]|plant|abstract[110]	new[108]|new|new[110]	_	_
19-24	1824-1836	preparedness	event[108]|abstract[110]	new[108]|new[110]	_	_
19-25	1837-1839	he	person	giv	coref	20-4
19-26	1840-1843	was	_	_	_	_
19-27	1844-1851	shunned	_	_	_	_
19-28	1852-1854	by	_	_	_	_
19-29	1855-1860	other	person[113]	giv[113]	_	_
19-30	1861-1868	vaccine	substance|person[113]	giv|giv[113]	coref	21-17[129_0]
19-31	1869-1880	researchers	person[113]	giv[113]	_	_
19-32	1881-1884	and	_	_	_	_
19-33	1885-1888	ate	_	_	_	_
19-34	1889-1894	alone	_	_	_	_
19-35	1895-1896	.	_	_	_	_
19-36	1897-1898	[	_	_	_	_
19-37	1899-1900	1	abstract	giv	coref	21-26
19-38	1901-1902	]	_	_	_	_

#Text=Reviews led by Jefferson have concluded that there is insufficient evidence to show that influenza vaccines reduce mortality or infection rates . [ 6 ]
20-1	1903-1910	Reviews	abstract	giv	_	_
20-2	1911-1914	led	_	_	_	_
20-3	1915-1917	by	_	_	_	_
20-4	1918-1927	Jefferson	person	giv	ana	21-1
20-5	1928-1932	have	_	_	_	_
20-6	1933-1942	concluded	_	_	_	_
20-7	1943-1947	that	_	_	_	_
20-8	1948-1953	there	_	_	_	_
20-9	1954-1956	is	_	_	_	_
20-10	1957-1969	insufficient	abstract[117]	giv[117]	_	_
20-11	1970-1978	evidence	abstract[117]	giv[117]	_	_
20-12	1979-1981	to	_	_	_	_
20-13	1982-1986	show	_	_	_	_
20-14	1987-1991	that	_	_	_	_
20-15	1992-2001	influenza	abstract|substance[119]	giv|giv[119]	coref|coref|coref|coref	21-18|21-31[133_119]|21-18|21-31[133_119]
20-16	2002-2010	vaccines	substance[119]	giv[119]	_	_
20-17	2011-2017	reduce	_	_	_	_
20-18	2018-2027	mortality	quantity	new	_	_
20-19	2028-2030	or	_	_	_	_
20-20	2031-2040	infection	abstract|quantity[122]	new|new[122]	coref|coref	21-11[127_122]|21-11[127_122]
20-21	2041-2046	rates	quantity[122]	new[122]	_	_
20-22	2047-2048	.	_	_	_	_
20-23	2049-2050	[	_	_	_	_
20-24	2051-2052	6	quantity	new	coref	26-22
20-25	2053-2054	]	_	_	_	_

#Text=He has said that the studies claiming large reductions in mortality rates as a result of the influenza vaccine are " rubbish " , [ 1 ] and that " influenza vaccines are about marketing and not science " . [ 7 ]
21-1	2055-2057	He	person	giv	ana	22-1
21-2	2058-2061	has	_	_	_	_
21-3	2062-2066	said	_	_	_	_
21-4	2067-2071	that	_	_	_	_
21-5	2072-2075	the	abstract[125]	new[125]	coref	21-22[0_125]
21-6	2076-2083	studies	abstract[125]	new[125]	_	_
21-7	2084-2092	claiming	_	_	_	_
21-8	2093-2098	large	abstract[126]	new[126]	_	_
21-9	2099-2109	reductions	abstract[126]	new[126]	_	_
21-10	2110-2112	in	abstract[126]	new[126]	_	_
21-11	2113-2122	mortality	abstract[126]|quantity[127]	new[126]|giv[127]	_	_
21-12	2123-2128	rates	abstract[126]|quantity[127]	new[126]|giv[127]	_	_
21-13	2129-2131	as	_	_	_	_
21-14	2132-2133	a	_	_	_	_
21-15	2134-2140	result	_	_	_	_
21-16	2141-2143	of	_	_	_	_
21-17	2144-2147	the	substance[129]	giv[129]	_	_
21-18	2148-2157	influenza	abstract|substance[129]	giv|giv[129]	coref	21-31
21-19	2158-2165	vaccine	substance[129]	giv[129]	_	_
21-20	2166-2169	are	_	_	_	_
21-21	2170-2171	"	_	_	_	_
21-22	2172-2179	rubbish	abstract	giv	_	_
21-23	2180-2181	"	_	_	_	_
21-24	2182-2183	,	_	_	_	_
21-25	2184-2185	[	_	_	_	_
21-26	2186-2187	1	abstract	giv	coref	22-30
21-27	2188-2189	]	_	_	_	_
21-28	2190-2193	and	_	_	_	_
21-29	2194-2198	that	_	_	_	_
21-30	2199-2200	"	_	_	_	_
21-31	2201-2210	influenza	abstract|substance[133]	giv|giv[133]	coref|coref|coref|coref	22-15[140_133]|32-2|22-15[140_133]|32-2
21-32	2211-2219	vaccines	substance[133]	giv[133]	_	_
21-33	2220-2223	are	_	_	_	_
21-34	2224-2229	about	_	_	_	_
21-35	2230-2239	marketing	_	_	_	_
21-36	2240-2243	and	_	_	_	_
21-37	2244-2247	not	_	_	_	_
21-38	2248-2255	science	abstract	new	_	_
21-39	2256-2257	"	_	_	_	_
21-40	2258-2259	.	_	_	_	_
21-41	2260-2261	[	_	_	_	_
21-42	2262-2263	7	abstract	new	_	_
21-43	2264-2265	]	_	_	_	_

#Text=He has called repeatedly for placebo-controlled randomized clinical trials to prove the efficacy of flu vaccines , a position that most in the field hold as unethical . [ 1 ]
22-1	2266-2268	He	person	giv	ana	23-1
22-2	2269-2272	has	_	_	_	_
22-3	2273-2279	called	_	_	_	_
22-4	2280-2290	repeatedly	_	_	_	_
22-5	2291-2294	for	_	_	_	_
22-6	2295-2313	placebo-controlled	abstract[137]	giv[137]	_	_
22-7	2314-2324	randomized	abstract[137]	giv[137]	_	_
22-8	2325-2333	clinical	abstract[137]	giv[137]	_	_
22-9	2334-2340	trials	abstract[137]	giv[137]	_	_
22-10	2341-2343	to	_	_	_	_
22-11	2344-2349	prove	_	_	_	_
22-12	2350-2353	the	abstract[138]	new[138]	_	_
22-13	2354-2362	efficacy	abstract[138]	new[138]	_	_
22-14	2363-2365	of	abstract[138]	new[138]	_	_
22-15	2366-2369	flu	abstract[138]|animal|substance[140]	new[138]|new|giv[140]	coref|coref|coref|coref	23-4|23-4[148_140]|23-4|23-4[148_140]
22-16	2370-2378	vaccines	abstract[138]|substance[140]	new[138]|giv[140]	_	_
22-17	2379-2380	,	_	_	_	_
22-18	2381-2382	a	abstract[141]	new[141]	_	_
22-19	2383-2391	position	abstract[141]	new[141]	_	_
22-20	2392-2396	that	_	_	_	_
22-21	2397-2401	most	_	_	_	_
22-22	2402-2404	in	_	_	_	_
22-23	2405-2408	the	abstract[142]	new[142]	_	_
22-24	2409-2414	field	abstract[142]	new[142]	_	_
22-25	2415-2419	hold	abstract[142]|abstract	new[142]|new	_	_
22-26	2420-2422	as	abstract[142]	new[142]	_	_
22-27	2423-2432	unethical	abstract[142]	new[142]	_	_
22-28	2433-2434	.	_	_	_	_
22-29	2435-2436	[	_	_	_	_
22-30	2437-2438	1	abstract	giv	coref	23-14
22-31	2439-2440	]	_	_	_	_

#Text=His views on flu vaccines are opposed by the medical establishment . [ 1 ]
23-1	2441-2444	His	person|abstract[146]	giv|giv[146]	coref|coref	25-1[152_0]|25-1[152_0]
23-2	2445-2450	views	abstract[146]	giv[146]	_	_
23-3	2451-2453	on	abstract[146]	giv[146]	_	_
23-4	2454-2457	flu	abstract[146]|abstract|substance[148]	giv[146]|giv|giv[148]	coref|coref	32-1[183_148]|32-1[183_148]
23-5	2458-2466	vaccines	abstract[146]|substance[148]	giv[146]|giv[148]	_	_
23-6	2467-2470	are	_	_	_	_
23-7	2471-2478	opposed	_	_	_	_
23-8	2479-2481	by	_	_	_	_
23-9	2482-2485	the	organization[149]	new[149]	_	_
23-10	2486-2493	medical	organization[149]	new[149]	_	_
23-11	2494-2507	establishment	organization[149]	new[149]	_	_
23-12	2508-2509	.	_	_	_	_
23-13	2510-2511	[	_	_	_	_
23-14	2512-2513	1	abstract	giv	_	_
23-15	2514-2515	]	_	_	_	_

#Text=Publications
24-1	2516-2528	Publications	abstract	new	_	_

#Text=Jefferson , T ; Alderson , P ; Wager , E ; Davidoff , F ( 5 June 2002 ) .
25-1	2529-2538	Jefferson	person[152]	giv[152]	coref	27-1[164_152]
25-2	2539-2540	,	person[152]	giv[152]	_	_
25-3	2541-2542	T	person[152]	giv[152]	_	_
25-4	2543-2544	;	_	_	_	_
25-5	2545-2553	Alderson	_	_	_	_
25-6	2554-2555	,	_	_	_	_
25-7	2556-2557	P	person	new	_	_
25-8	2558-2559	;	_	_	_	_
25-9	2560-2565	Wager	_	_	_	_
25-10	2566-2567	,	_	_	_	_
25-11	2568-2569	E	_	_	_	_
25-12	2570-2571	;	_	_	_	_
25-13	2572-2580	Davidoff	_	_	_	_
25-14	2581-2582	,	_	_	_	_
25-15	2583-2584	F	person	new	coref	27-11
25-16	2585-2586	(	_	_	_	_
25-17	2587-2588	5	_	_	_	_
25-18	2589-2593	June	time	new	coref	27-14
25-19	2594-2598	2002	time	new	coref	27-15
25-20	2599-2600	)	_	_	_	_
25-21	2601-2602	.	_	_	_	_

#Text=" Effects of editorial peer review : a systematic review " . JAMA . 287 ( 21 ) : 2784 – 6 . doi : 10.1001/jama.287.21.2784 . PMID 12038911 .
26-1	2603-2604	"	_	_	_	_
26-2	2605-2612	Effects	abstract[157]	new[157]	appos	26-8[160_157]
26-3	2613-2615	of	abstract[157]	new[157]	_	_
26-4	2616-2625	editorial	abstract[157]|abstract[159]	new[157]|giv[159]	coref	29-5[170_159]
26-5	2626-2630	peer	abstract[157]|person|abstract[159]	new[157]|new|giv[159]	coref	29-6
26-6	2631-2637	review	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
26-7	2638-2639	:	_	_	_	_
26-8	2640-2641	a	abstract[160]	giv[160]	_	_
26-9	2642-2652	systematic	abstract[160]	giv[160]	_	_
26-10	2653-2659	review	abstract[160]	giv[160]	_	_
26-11	2660-2661	"	_	_	_	_
26-12	2662-2663	.	_	_	_	_
26-13	2664-2668	JAMA	organization[161]	new[161]	_	_
26-14	2669-2670	.	organization[161]	new[161]	_	_
26-15	2671-2674	287	organization[161]	new[161]	_	_
26-16	2675-2676	(	organization[161]	new[161]	_	_
26-17	2677-2679	21	organization[161]	new[161]	_	_
26-18	2680-2681	)	organization[161]	new[161]	_	_
26-19	2682-2683	:	_	_	_	_
26-20	2684-2688	2784	_	_	_	_
26-21	2689-2690	–	_	_	_	_
26-22	2691-2692	6	quantity	giv	_	_
26-23	2693-2694	.	_	_	_	_
26-24	2695-2698	doi	_	_	_	_
26-25	2699-2700	:	_	_	_	_
26-26	2701-2725	10.1001/jama.287.21.2784	_	_	_	_
26-27	2726-2727	.	_	_	_	_
26-28	2728-2732	PMID	abstract	new	coref	29-25
26-29	2733-2741	12038911	_	_	_	_
26-30	2742-2743	.	_	_	_	_

#Text=Jefferson , T ; Wager , E ; Davidoff , F ( 5 June 2002 ) .
27-1	2744-2753	Jefferson	person[164]	giv[164]	coref	30-1[175_164]
27-2	2754-2755	,	person[164]	giv[164]	_	_
27-3	2756-2757	T	person[164]	giv[164]	_	_
27-4	2758-2759	;	_	_	_	_
27-5	2760-2765	Wager	_	_	_	_
27-6	2766-2767	,	_	_	_	_
27-7	2768-2769	E	_	_	_	_
27-8	2770-2771	;	_	_	_	_
27-9	2772-2780	Davidoff	_	_	_	_
27-10	2781-2782	,	_	_	_	_
27-11	2783-2784	F	person	giv	_	_
27-12	2785-2786	(	_	_	_	_
27-13	2787-2788	5	_	_	_	_
27-14	2789-2793	June	time	giv	_	_
27-15	2794-2798	2002	time	giv	_	_
27-16	2799-2800	)	_	_	_	_
27-17	2801-2802	.	_	_	_	_

#Text="
28-1	2803-2804	"	_	_	_	_

#Text=Measuring the quality of editorial peer review " . JAMA . 287 ( 21 ) : 2786 – 90 . doi : 10.1001/jama.287.21.2786 . PMID 12038912 .
29-1	2805-2814	Measuring	_	_	_	_
29-2	2815-2818	the	abstract[168]	new[168]	_	_
29-3	2819-2826	quality	abstract[168]	new[168]	_	_
29-4	2827-2829	of	abstract[168]	new[168]	_	_
29-5	2830-2839	editorial	abstract[168]|abstract[170]	new[168]|giv[170]	coref	36-14[215_170]
29-6	2840-2844	peer	abstract[168]|person|abstract[170]	new[168]|giv|giv[170]	_	_
29-7	2845-2851	review	abstract[168]|abstract[170]	new[168]|giv[170]	_	_
29-8	2852-2853	"	_	_	_	_
29-9	2854-2855	.	_	_	_	_
29-10	2856-2860	JAMA	_	_	_	_
29-11	2861-2862	.	_	_	_	_
29-12	2863-2866	287	_	_	_	_
29-13	2867-2868	(	_	_	_	_
29-14	2869-2871	21	_	_	_	_
29-15	2872-2873	)	_	_	_	_
29-16	2874-2875	:	_	_	_	_
29-17	2876-2880	2786	abstract[171]	new[171]	_	_
29-18	2881-2882	–	abstract[171]	new[171]	_	_
29-19	2883-2885	90	abstract[171]|quantity	new[171]|new	_	_
29-20	2886-2887	.	_	_	_	_
29-21	2888-2891	doi	abstract[173]	new[173]	_	_
29-22	2892-2893	:	abstract[173]	new[173]	_	_
29-23	2894-2918	10.1001/jama.287.21.2786	abstract[173]	new[173]	_	_
29-24	2919-2920	.	abstract[173]	new[173]	_	_
29-25	2921-2925	PMID	abstract[173]|abstract	new[173]|giv	coref	34-17[193_0]
29-26	2926-2934	12038912	abstract[173]	new[173]	_	_
29-27	2935-2936	.	_	_	_	_

#Text=Jefferson , T ; Di Pietrantonj , C ; Debalini , MG ; Rivetti , A ; Demicheli , V ( July 2009 ) .
30-1	2937-2946	Jefferson	person[175]	giv[175]	coref	35-1[194_175]
30-2	2947-2948	,	person[175]	giv[175]	_	_
30-3	2949-2950	T	person[175]	giv[175]	_	_
30-4	2951-2952	;	person[175]	giv[175]	_	_
30-5	2953-2955	Di	person[175]|person	giv[175]|new	_	_
30-6	2956-2967	Pietrantonj	person[175]	giv[175]	_	_
30-7	2968-2969	,	person[175]	giv[175]	_	_
30-8	2970-2971	C	person[175]|person	giv[175]|new	_	_
30-9	2972-2973	;	person[175]	giv[175]	_	_
30-10	2974-2982	Debalini	person[175]	giv[175]	_	_
30-11	2983-2984	,	person[175]	giv[175]	_	_
30-12	2985-2987	MG	person[175]	giv[175]	_	_
30-13	2988-2989	;	person[175]	giv[175]	_	_
30-14	2990-2997	Rivetti	person[175]	giv[175]	_	_
30-15	2998-2999	,	person[175]	giv[175]	_	_
30-16	3000-3001	A	person[175]|person[178]	giv[175]|new[178]	appos	30-20[0_178]
30-17	3002-3003	;	person[175]|person[178]	giv[175]|new[178]	_	_
30-18	3004-3013	Demicheli	person[175]|person[178]	giv[175]|new[178]	_	_
30-19	3014-3015	,	_	_	_	_
30-20	3016-3017	V	person	giv	_	_
30-21	3018-3019	(	_	_	_	_
30-22	3020-3024	July	time[180]	new[180]	_	_
30-23	3025-3029	2009	time[180]|time	new[180]|giv	coref	35-44
30-24	3030-3031	)	_	_	_	_
30-25	3032-3033	.	_	_	_	_

#Text="
31-1	3034-3035	"	_	_	_	_

#Text=Inactivated influenza vaccines : methods , policies , and politics " .
32-1	3036-3047	Inactivated	substance[183]	giv[183]	appos	32-5[185_183]
32-2	3048-3057	influenza	abstract|substance[183]	giv|giv[183]	_	_
32-3	3058-3066	vaccines	substance[183]	giv[183]	_	_
32-4	3067-3068	:	_	_	_	_
32-5	3069-3076	methods	abstract|substance[185]	new|giv[185]	_	_
32-6	3077-3078	,	substance[185]	giv[185]	_	_
32-7	3079-3087	policies	substance[185]|abstract	giv[185]|new	_	_
32-8	3088-3089	,	substance[185]	giv[185]	_	_
32-9	3090-3093	and	substance[185]	giv[185]	_	_
32-10	3094-3102	politics	substance[185]|abstract	giv[185]|new	_	_
32-11	3103-3104	"	_	_	_	_
32-12	3105-3106	.	_	_	_	_

#Text=Journal of Clinical Epidemiology
33-1	3107-3114	Journal	abstract[188]	new[188]	_	_
33-2	3115-3117	of	abstract[188]	new[188]	_	_
33-3	3118-3126	Clinical	abstract[188]|abstract[189]	new[188]|new[189]	_	_
33-4	3127-3139	Epidemiology	abstract[188]|abstract[189]	new[188]|new[189]	_	_

#Text=. 62 ( 7 ) : 677 – 86 . doi : 10.1016/j . jclinepi.2008.07.001 . PMID 19124222 .
34-1	3140-3141	.	_	_	_	_
34-2	3142-3144	62	time[190]	new[190]	_	_
34-3	3145-3146	(	time[190]	new[190]	_	_
34-4	3147-3148	7	time[190]	new[190]	_	_
34-5	3149-3150	)	time[190]	new[190]	_	_
34-6	3151-3152	:	_	_	_	_
34-7	3153-3156	677	quantity[191]	new[191]	_	_
34-8	3157-3158	–	quantity[191]	new[191]	_	_
34-9	3159-3161	86	quantity[191]|quantity	new[191]|new	_	_
34-10	3162-3163	.	_	_	_	_
34-11	3164-3167	doi	_	_	_	_
34-12	3168-3169	:	_	_	_	_
34-13	3170-3179	10.1016/j	_	_	_	_
34-14	3180-3181	.	_	_	_	_
34-15	3182-3202	jclinepi.2008.07.001	_	_	_	_
34-16	3203-3204	.	_	_	_	_
34-17	3205-3209	PMID	abstract[193]	giv[193]	coref	46-16[0_193]
34-18	3210-3218	19124222	abstract[193]	giv[193]	_	_
34-19	3219-3220	.	_	_	_	_

#Text=Jefferson , T. ; Del Mar , C. ; Dooley , L. ; Ferroni , E. ; Al-Ansary , L. A ; Bawazeer , G. A ; van Driel , M. L ; Foxlee , R. ; Rivetti , A. ( 22 September 2009 ) .
35-1	3221-3230	Jefferson	person[194]	giv[194]	_	_
35-2	3231-3232	,	person[194]	giv[194]	_	_
35-3	3233-3235	T.	person[194]	giv[194]	_	_
35-4	3236-3237	;	person[194]	giv[194]	_	_
35-5	3238-3241	Del	person[194]|person[195]	giv[194]|new[195]	_	_
35-6	3242-3245	Mar	person[194]|person[195]	giv[194]|new[195]	_	_
35-7	3246-3247	,	person[194]|person[195]	giv[194]|new[195]	_	_
35-8	3248-3250	C.	person[194]|person[195]|person	giv[194]|new[195]|new	_	_
35-9	3251-3252	;	person[194]	giv[194]	_	_
35-10	3253-3259	Dooley	person[194]|person[197]	giv[194]|new[197]	_	_
35-11	3260-3261	,	person[194]|person[197]	giv[194]|new[197]	_	_
35-12	3262-3264	L.	person[194]|person[197]	giv[194]|new[197]	_	_
35-13	3265-3266	;	person[194]	giv[194]	_	_
35-14	3267-3274	Ferroni	person[194]|person[198]	giv[194]|new[198]	_	_
35-15	3275-3276	,	person[194]|person[198]	giv[194]|new[198]	_	_
35-16	3277-3279	E.	person[194]|person[198]|person	giv[194]|new[198]|new	_	_
35-17	3280-3281	;	person[194]	giv[194]	_	_
35-18	3282-3291	Al-Ansary	person[194]|person	giv[194]|new	_	_
35-19	3292-3293	,	person[194]	giv[194]	_	_
35-20	3294-3296	L.	person[194]|person	giv[194]|new	_	_
35-21	3297-3298	A	person[194]	giv[194]	_	_
35-22	3299-3300	;	person[194]	giv[194]	_	_
35-23	3301-3309	Bawazeer	person[194]|person	giv[194]|new	_	_
35-24	3310-3311	,	person[194]	giv[194]	_	_
35-25	3312-3314	G.	person[194]|person	giv[194]|new	_	_
35-26	3315-3316	A	person[194]	giv[194]	_	_
35-27	3317-3318	;	person[194]	giv[194]	_	_
35-28	3319-3322	van	person[194]|object[204]	giv[194]|new[204]	_	_
35-29	3323-3328	Driel	person[194]|object[204]	giv[194]|new[204]	_	_
35-30	3329-3330	,	person[194]	giv[194]	_	_
35-31	3331-3333	M.	person[194]|person[205]	giv[194]|new[205]	_	_
35-32	3334-3335	L	person[194]|person[205]	giv[194]|new[205]	_	_
35-33	3336-3337	;	person[194]	giv[194]	_	_
35-34	3338-3344	Foxlee	person[194]|person	giv[194]|new	_	_
35-35	3345-3346	,	person[194]	giv[194]	_	_
35-36	3347-3349	R.	person[194]|person	giv[194]|new	_	_
35-37	3350-3351	;	person[194]	giv[194]	_	_
35-38	3352-3359	Rivetti	person[194]|person	giv[194]|new	appos	35-40
35-39	3360-3361	,	_	_	_	_
35-40	3362-3364	A.	person	giv	_	_
35-41	3365-3366	(	_	_	_	_
35-42	3367-3369	22	_	_	_	_
35-43	3370-3379	September	time[210]	new[210]	_	_
35-44	3380-3384	2009	time[210]|time	new[210]|giv	_	_
35-45	3385-3386	)	_	_	_	_
35-46	3387-3388	.	_	_	_	_

#Text=" Physical interventions to interrupt or reduce the spread of respiratory viruses : systematic review "
36-1	3389-3390	"	_	_	_	_
36-2	3391-3399	Physical	event[212]	new[212]	_	_
36-3	3400-3413	interventions	event[212]	new[212]	_	_
36-4	3414-3416	to	_	_	_	_
36-5	3417-3426	interrupt	_	_	_	_
36-6	3427-3429	or	_	_	_	_
36-7	3430-3436	reduce	_	_	_	_
36-8	3437-3440	the	abstract[213]	new[213]	_	_
36-9	3441-3447	spread	abstract[213]	new[213]	_	_
36-10	3448-3450	of	abstract[213]	new[213]	_	_
36-11	3451-3462	respiratory	abstract[213]|object[214]	new[213]|new[214]	_	_
36-12	3463-3470	viruses	abstract[213]|object[214]	new[213]|new[214]	_	_
36-13	3471-3472	:	_	_	_	_
36-14	3473-3483	systematic	abstract[215]	giv[215]	_	_
36-15	3484-3490	review	abstract[215]	giv[215]	_	_
36-16	3491-3492	"	_	_	_	_

#Text=.
37-1	3493-3494	.	_	_	_	_

#Text=BMJ
38-1	3495-3498	BMJ	organization	new	_	_

#Text=. 339 ( sep21 1 ) : b3675 – b3675 . doi : 10.1136/bmj . b3675 . PMC 2190272 .
39-1	3499-3500	.	_	_	_	_
39-2	3501-3504	339	quantity	new	_	_
39-3	3505-3506	(	_	_	_	_
39-4	3507-3512	sep21	abstract[218]	new[218]	_	_
39-5	3513-3514	1	abstract[218]	new[218]	_	_
39-6	3515-3516	)	_	_	_	_
39-7	3517-3518	:	_	_	_	_
39-8	3519-3524	b3675	abstract[219]	new[219]	_	_
39-9	3525-3526	–	abstract[219]	new[219]	_	_
39-10	3527-3532	b3675	abstract[219]|abstract	new[219]|new	_	_
39-11	3533-3534	.	_	_	_	_
39-12	3535-3538	doi	animal[221]	new[221]	_	_
39-13	3539-3540	:	animal[221]	new[221]	_	_
39-14	3541-3552	10.1136/bmj	animal[221]	new[221]	_	_
39-15	3553-3554	.	animal[221]	new[221]	_	_
39-16	3555-3560	b3675	animal[221]	new[221]	_	_
39-17	3561-3562	.	animal[221]	new[221]	_	_
39-18	3563-3566	PMC	animal[221]|abstract	new[221]|new	coref	46-13
39-19	3567-3574	2190272	animal[221]	new[221]	_	_
39-20	3575-3576	.	_	_	_	_

#Text=Chan , An-Wen ; Song , Fujian ; Vickers , Andrew ; Jefferson , Tom ; Dickersin , Kay ; Gøtzsche , Peter C ; Krumholz , Harlan M ; Ghersi , Davina ; van der Worp , H Bart ( January 2014 ) .
40-1	3577-3581	Chan	person	new	appos	40-3
40-2	3582-3583	,	_	_	_	_
40-3	3584-3590	An-Wen	person	giv	_	_
40-4	3591-3592	;	_	_	_	_
40-5	3593-3597	Song	_	_	_	_
40-6	3598-3599	,	_	_	_	_
40-7	3600-3606	Fujian	place	new	_	_
40-8	3607-3608	;	_	_	_	_
40-9	3609-3616	Vickers	_	_	_	_
40-10	3617-3618	,	_	_	_	_
40-11	3619-3625	Andrew	_	_	_	_
40-12	3626-3627	;	_	_	_	_
40-13	3628-3637	Jefferson	_	_	_	_
40-14	3638-3639	,	_	_	_	_
40-15	3640-3643	Tom	_	_	_	_
40-16	3644-3645	;	_	_	_	_
40-17	3646-3655	Dickersin	_	_	_	_
40-18	3656-3657	,	_	_	_	_
40-19	3658-3661	Kay	_	_	_	_
40-20	3662-3663	;	_	_	_	_
40-21	3664-3672	Gøtzsche	_	_	_	_
40-22	3673-3674	,	_	_	_	_
40-23	3675-3680	Peter	_	_	_	_
40-24	3681-3682	C	_	_	_	_
40-25	3683-3684	;	_	_	_	_
40-26	3685-3693	Krumholz	_	_	_	_
40-27	3694-3695	,	_	_	_	_
40-28	3696-3702	Harlan	_	_	_	_
40-29	3703-3704	M	abstract	new	_	_
40-30	3705-3706	;	_	_	_	_
40-31	3707-3713	Ghersi	_	_	_	_
40-32	3714-3715	,	_	_	_	_
40-33	3716-3722	Davina	_	_	_	_
40-34	3723-3724	;	_	_	_	_
40-35	3725-3728	van	_	_	_	_
40-36	3729-3732	der	_	_	_	_
40-37	3733-3737	Worp	_	_	_	_
40-38	3738-3739	,	_	_	_	_
40-39	3740-3741	H	person	new	_	_
40-40	3742-3746	Bart	_	_	_	_
40-41	3747-3748	(	_	_	_	_
40-42	3749-3756	January	time[228]	new[228]	_	_
40-43	3757-3761	2014	time[228]|time	new[228]|new	_	_
40-44	3762-3763	)	_	_	_	_
40-45	3764-3765	.	_	_	_	_

#Text=" Increasing value and reducing waste : addressing inaccessible research "
41-1	3766-3767	"	_	_	_	_
41-2	3768-3778	Increasing	_	_	_	_
41-3	3779-3784	value	abstract	new	_	_
41-4	3785-3788	and	_	_	_	_
41-5	3789-3797	reducing	_	_	_	_
41-6	3798-3803	waste	abstract	new	_	_
41-7	3804-3805	:	_	_	_	_
41-8	3806-3816	addressing	_	_	_	_
41-9	3817-3829	inaccessible	abstract[232]	new[232]	_	_
41-10	3830-3838	research	abstract[232]	new[232]	_	_
41-11	3839-3840	"	_	_	_	_

#Text=.
42-1	3841-3842	.	_	_	_	_

#Text=The Lancet
43-1	3843-3846	The	abstract[233]	new[233]	_	_
43-2	3847-3853	Lancet	abstract[233]	new[233]	_	_

#Text=.
44-1	3854-3855	.	_	_	_	_

#Text=383
45-1	3856-3859	383	quantity	new	_	_

#Text=( 9913 ) : 257 – 266 . doi : 10.1016/S0140-6736(13)62296-5 . PMC 4533904 . PMID 24411650 .
46-1	3860-3861	(	_	_	_	_
46-2	3862-3866	9913	quantity	new	_	_
46-3	3867-3868	)	_	_	_	_
46-4	3869-3870	:	_	_	_	_
46-5	3871-3874	257	quantity[236]	new[236]	_	_
46-6	3875-3876	–	quantity[236]	new[236]	_	_
46-7	3877-3880	266	quantity[236]|quantity	new[236]|new	_	_
46-8	3881-3882	.	_	_	_	_
46-9	3883-3886	doi	_	_	_	_
46-10	3887-3888	:	_	_	_	_
46-11	3889-3918	10.1016/S0140-6736(13)62296-5	_	_	_	_
46-12	3919-3920	.	_	_	_	_
46-13	3921-3924	PMC	abstract	giv	_	_
46-14	3925-3932	4533904	_	_	_	_
46-15	3933-3934	.	_	_	_	_
46-16	3935-3939	PMID	abstract	giv	_	_
46-17	3940-3948	24411650	_	_	_	_
46-18	3949-3950	.	_	_	_	_

#Text=Doshi , P. ; Jefferson , T. ( 2 March 2015 ) .
47-1	3951-3956	Doshi	person[240]	new[240]	_	_
47-2	3957-3958	,	person[240]	new[240]	_	_
47-3	3959-3961	P.	person[240]|person	new[240]|new	appos	47-7
47-4	3962-3963	;	_	_	_	_
47-5	3964-3973	Jefferson	_	_	_	_
47-6	3974-3975	,	_	_	_	_
47-7	3976-3978	T.	person	giv	_	_
47-8	3979-3980	(	_	_	_	_
47-9	3981-3982	2	time[243]	new[243]	_	_
47-10	3983-3988	March	time[243]|time	new[243]|new	_	_
47-11	3989-3993	2015	time[243]|time	new[243]|new	_	_
47-12	3994-3995	)	_	_	_	_
47-13	3996-3997	.	_	_	_	_

#Text=" The evidence base for new drugs " . BMJ . 350 ( mar02 6 ) : h952 – h952 . doi : 10.1136/bmj . h952 .
48-1	3998-3999	"	abstract[247]	new[247]	_	_
48-2	4000-4003	The	abstract[247]	new[247]	_	_
48-3	4004-4012	evidence	abstract|abstract[247]	new|new[247]	_	_
48-4	4013-4017	base	abstract[247]	new[247]	_	_
48-5	4018-4021	for	abstract[247]	new[247]	_	_
48-6	4022-4025	new	abstract[247]|substance[248]	new[247]|new[248]	_	_
48-7	4026-4031	drugs	abstract[247]|substance[248]	new[247]|new[248]	_	_
48-8	4032-4033	"	abstract[247]	new[247]	_	_
48-9	4034-4035	.	abstract[247]	new[247]	_	_
48-10	4036-4039	BMJ	abstract[247]	new[247]	_	_
48-11	4040-4041	.	abstract[247]	new[247]	_	_
48-12	4042-4045	350	abstract[247]	new[247]	_	_
48-13	4046-4047	(	abstract[247]	new[247]	_	_
48-14	4048-4053	mar02	abstract[247]	new[247]	_	_
48-15	4054-4055	6	abstract[247]	new[247]	_	_
48-16	4056-4057	)	abstract[247]	new[247]	_	_
48-17	4058-4059	:	abstract[247]	new[247]	_	_
48-18	4060-4064	h952	abstract[247]	new[247]	_	_
48-19	4065-4066	–	abstract[247]	new[247]	_	_
48-20	4067-4071	h952	abstract[247]|abstract	new[247]|new	_	_
48-21	4072-4073	.	abstract[247]	new[247]	_	_
48-22	4074-4077	doi	abstract[247]	new[247]	_	_
48-23	4078-4079	:	abstract[247]	new[247]	_	_
48-24	4080-4091	10.1136/bmj	abstract[247]	new[247]	_	_
48-25	4092-4093	.	abstract[247]	new[247]	_	_
48-26	4094-4098	h952	abstract[247]	new[247]	_	_
48-27	4099-4100	.	_	_	_	_
